HomeMarket NewsUnforeseen Twists: Cue Biopharma Falls Short on EPS But Triumphs on Revenue...

Unforeseen Twists: Cue Biopharma Falls Short on EPS But Triumphs on Revenue in Q4 2023

Actionable Trade Ideas

always free

CUE stock - CUE Stock Earnings: Cue Biopharma Misses EPS, Beats Revenue for Q4 2023

Source: iQoncept / Shutterstock

Cue Biopharma (NASDAQ:CUE) has unveiled its performance for the fourth quarter of 2023.

  • Cue Biopharma fell short with earnings per share of -29 cents, slightly below the anticipated -28 cents.
  • The company excelled in revenue, raking in $1.82 million, surpassing the estimated revenue of $1.71 million by 6.49%.

InvestorPlace Earnings initiates an innovative approach by utilizing TradeSmith data to automate coverage of quarterly earnings reports. By promptly sifting through financial complexities and extracting vital details like earnings per share and revenue comparisons, we strive to present a comprehensive outlook devoid of manual interference. To address any discrepancies or concerns, please reach out to us at [email protected].


Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/04/cue-stock-earnings-cue-biopharma-for-q4-of-2023/.

©2024 InvestorPlace Media, LLC

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.